Logo image of NVNO

ENVVENO MEDICAL CORP (NVNO) Stock Fundamental Analysis

USA - NASDAQ:NVNO - US29415J1060 - Common Stock

0.7049 USD
+0.01 (+1.1%)
Last: 10/31/2025, 8:04:05 PM
0.71 USD
+0.01 (+0.72%)
After Hours: 10/31/2025, 8:04:05 PM
Fundamental Rating

2

Taking everything into account, NVNO scores 2 out of 10 in our fundamental rating. NVNO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NVNO as it has an excellent financial health rating, but there are worries on the profitability. NVNO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NVNO had negative earnings in the past year.
NVNO had a negative operating cash flow in the past year.
NVNO had negative earnings in each of the past 5 years.
NVNO had a negative operating cash flow in each of the past 5 years.
NVNO Yearly Net Income VS EBIT VS OCF VS FCFNVNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

NVNO's Return On Assets of -63.07% is on the low side compared to the rest of the industry. NVNO is outperformed by 69.31% of its industry peers.
With a Return On Equity value of -69.78%, NVNO perfoms like the industry average, outperforming 43.39% of the companies in the same industry.
Industry RankSector Rank
ROA -63.07%
ROE -69.78%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
NVNO Yearly ROA, ROE, ROICNVNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NVNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVNO Yearly Profit, Operating, Gross MarginsNVNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

NVNO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NVNO has more shares outstanding
There is no outstanding debt for NVNO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NVNO Yearly Shares OutstandingNVNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
NVNO Yearly Total Debt VS Total AssetsNVNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

NVNO has an Altman-Z score of -5.10. This is a bad value and indicates that NVNO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.10, NVNO is doing worse than 69.31% of the companies in the same industry.
NVNO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.1
ROIC/WACCN/A
WACCN/A
NVNO Yearly LT Debt VS Equity VS FCFNVNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 11.81 indicates that NVNO has no problem at all paying its short term obligations.
With an excellent Current ratio value of 11.81, NVNO belongs to the best of the industry, outperforming 95.24% of the companies in the same industry.
A Quick Ratio of 11.81 indicates that NVNO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 11.81, NVNO belongs to the best of the industry, outperforming 96.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.81
Quick Ratio 11.81
NVNO Yearly Current Assets VS Current LiabilitesNVNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.08% over the past year.
EPS 1Y (TTM)16.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NVNO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.86% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.26%
EPS Next 2Y9.4%
EPS Next 3Y12.02%
EPS Next 5Y12.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVNO Yearly Revenue VS EstimatesNVNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2018 2019 2026 2027 2028 5M 10M 15M 20M 25M
NVNO Yearly EPS VS EstimatesNVNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NVNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVNO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVNO Price Earnings VS Forward Price EarningsNVNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVNO Per share dataNVNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

NVNO's earnings are expected to grow with 12.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.4%
EPS Next 3Y12.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVNO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENVVENO MEDICAL CORP

NASDAQ:NVNO (10/31/2025, 8:04:05 PM)

After market: 0.71 +0.01 (+0.72%)

0.7049

+0.01 (+1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-29 2025-10-29/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners23.33%
Inst Owner Change-3.85%
Ins Owners0.81%
Ins Owner Change0%
Market Cap13.57M
Revenue(TTM)N/A
Net Income(TTM)-23068000
Analysts43.33
Price Target12.75 (1708.77%)
Short Float %11.86%
Short Ratio1.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.51%
Min EPS beat(2)-15.55%
Max EPS beat(2)36.56%
EPS beat(4)2
Avg EPS beat(4)8.25%
Min EPS beat(4)-15.55%
Max EPS beat(4)36.56%
EPS beat(8)6
Avg EPS beat(8)13%
EPS beat(12)7
Avg EPS beat(12)6.26%
EPS beat(16)8
Avg EPS beat(16)-14.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.07%
ROE -69.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -129.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.81
Quick Ratio 11.81
Altman-Z -5.1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)30.57%
Cap/Depr(5y)103.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.45%
EPS Next Y13.26%
EPS Next 2Y9.4%
EPS Next 3Y12.02%
EPS Next 5Y12.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.99%
OCF growth 3YN/A
OCF growth 5YN/A

ENVVENO MEDICAL CORP / NVNO FAQ

Can you provide the ChartMill fundamental rating for ENVVENO MEDICAL CORP?

ChartMill assigns a fundamental rating of 2 / 10 to NVNO.


What is the valuation status of ENVVENO MEDICAL CORP (NVNO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ENVVENO MEDICAL CORP (NVNO). This can be considered as Overvalued.


How profitable is ENVVENO MEDICAL CORP (NVNO) stock?

ENVVENO MEDICAL CORP (NVNO) has a profitability rating of 0 / 10.


What is the financial health of ENVVENO MEDICAL CORP (NVNO) stock?

The financial health rating of ENVVENO MEDICAL CORP (NVNO) is 7 / 10.